Skip to main content
Premium Trial:

Request an Annual Quote

A Light on p53

Premium

In a new study published in Cancer Cell, researchers from the Cancer Institute of New Jersey in New Brunswick and the Institute for Advanced Study in Princeton, NJ, have identified two compounds that may correct a common cancer-associated mutation, reports The Star-Ledger's Seth Augenstein. The p53 mutation is found in many different cancers, and it causes cancer cells to spread and become malignant. The compounds, thiosemicarbazones, have been around for decades, and have been studied as possible cancer therapeutics before, Augenstein says, but have not been connected to this specific p53 mutation.

For this study, the team did a literature search to find compounds that could affect p53, and when they tried thiosemicarbazones in mice implanted with human p53-mutated tumor cells, they found that the tumors stopped growing or shrank, and that healthy cells remained unaffected, Augenstein says. Lead author Darren Carpizo tells him that "if you had a gene you wanted to restore the function of in a human tumor as a mode of treatment, p53 has been high on the list for a long time."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.